• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Natural Disease Course of Ulcerative Colitis ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1093/ecco-jcc/jjy154
PMID :
30289522
Permalink :
http://hdl.handle.net/20.500.12210/4492
Title :
Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.
Author(s) :
Burisch, Johan [Auteur]
Katsanos Konstantinos, H [Auteur]
Christodoulou Dimitrios, K [Auteur]
Barros, Luisa [Auteur]
Magro, Fernando [Auteur]
Pedersen, Natalia [Auteur]
Kjeldsen, Jens [Auteur]
Vegh, Zsuzsanna [Auteur]
Lakatos Peter, Laszlo [Auteur]
Eriksson, Carl [Auteur]
Halfvarson, Jonas [Auteur]
Fumery, Mathurin [Auteur] refId
Gower, Corinne [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Brinar, Marko [Auteur]
Cukovic-Cavka, Silvija [Auteur]
Nikulina, Inna [Auteur]
Belousova, Elena [Auteur]
Myers, Sally [Auteur]
Sebastian, Shaji [Auteur]
Kiudelis, Gediminas [Auteur]
Kupcinskas, Limas [Auteur]
Schwartz, Doron [Auteur]
Odes, Selwyn [Auteur]
Kaimakliotis Ioannis, P [Auteur]
Valpiani, Daniela [Auteur]
D''inca, Renata [Auteur]
Salupere, Riina [Auteur]
Zammit Stefania, Chetcuti [Auteur]
Ellul, Pierre [Auteur]
Duricova, Dana [Auteur]
Bortlik, Martin [Auteur]
Goldis, Adrian [Auteur]
Kievit Hendrika Adriana, Linda [Auteur]
Toca, Alina [Auteur]
Turcan, Svetlana [Auteur]
Midjord, Jongerð [Auteur]
Nielsen Kari, Rubek [Auteur]
Winther Andersen, Karina [Auteur]
Andersen, Vibeke [Auteur]
Misra, Ravi [Auteur]
Arebi, Naila [Auteur]
Oksanen, Pia [Auteur]
Collin, Pekka [Auteur]
De Castro, Luisa [Auteur]
Hernandez, Vicent [Auteur]
Langholz, Ebbe [Auteur]
Munkholm, Pia [Auteur]
Journal title :
Journal of Crohn's & colitis
Abbreviated title :
J. Crohns Colitis
Publication date :
2018-10-05
ISSN :
1876-4479
1876-4479
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to ...
Show more >
Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort. Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis. Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8]. Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Collections :
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Research team(s) :
Inflammatory digestive disease : pathophysiology and therapeutic targets developement
IBD and environnemental factors : epidemiology and functional analyses
Submission date :
2019-03-01T14:07:56Z
Université de Lille

Mentions légales
Université de Lille © 2017